Go to Top


Calvert Holdings, Inc. Elects Dr. Donald A. Edmondson to its Board of Directors

Cary, N.C, (May 27, 2015) – Calvert Holdings, Inc., a privately held company focused on servicing early stage drug development companies, announced the election of Dr. Donald A. Edmondson, M.D. to its Board of Directors. Dr. Edmondson is a practicing anesthesiologist in the Raleigh, NC area and is a partner with the American Anesthesiology of North Carolina group. “I have known Don for many years and have found him to be a very skilled physician as well as an enterprising individual with many interests outside of the medical care industry”, said Russ McLauchlan, Executive Chairman and Founder of Calvert Holdings, Inc. “Calvert is undergoing a number of exciting transitional events

Read More

Calvert Holdings, Inc. Announces Executive Management Changes

CARY, NC (April 1, 2014).  Calvert Holdings, Inc. announced that Michael A. Recny, Ph.D., has been appointed Chief Executive Officer and has been elected a Director of the Company. He replaces Russ McLauchlan, who will become Executive Chairman and who will also now head the newly formed Executive Committee of Calvert Holdings, which will include Dr. Recny, Allan Reiss, President of Calvert Holdings, Inc., and Charles Spainhour, DVM, Ph.D, the Company’s Chief Scientific Officer. Dr. Recny will also continue to serve as President of Calvert Research, LLC, which is the investment arm of Calvert Holdings. Of these executive changes, Russ McLauchlan states “We founded Calvert Holdings, Inc. in 1996 with

Read More

Calvert Research Portfolio Company Oncoceutics, Inc. Receives FDA Clearance to Begin Phase I/II Trial of ONC201

CARY, NC (March 13, 2014): Calvert Research, LLC, a business unit of Calvert Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) recently accepted the Investigational New Drug (IND) application for the Phase I/II trial of ONC201, the lead experimental drug compound being developed by Oncoceutics, Inc., a Calvert Research portfolio company.  ONC201 will initially be studied in Phase I safety and dose ranging clinical studies in patients suffering from advanced cancer, including refractory solid tumors. ONC201 is a first-in-class small molecule compound that has shown impressive efficacy in a wide range of very aggressive animal tumor models such as glioblastoma multiforme, prostate cancer, melanoma, sarcomas, and mantle cell lymphoma.  ONC201

Read More